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Abstract We present the case of a 31-year-old
spina bifida patient presenting with a poorly differ-
entiated T3N1M0 bladder carcinoma with sarcoma-
toid differentiation in an auto-augmented bladder.
She underwent a radical cystectomy and a bilateral
lymph node dissection. However, only 10 months
after the onset of her symptoms, she died after major
lymphatic metastases had developed in the small
pelvis. This case report is the first on an adult spina
bifida patient developing bladder carcinoma after
detrusorectomy. It shows that bladder cancer also
occurs in patients who underwent detrusorectomy,
despite the fact that the risk is supposedly lower
than in patients who underwent enterocystoplasty.
Moreover, tumour spread to adjacent organs could
occur more rapidly in auto-augmented bladders
because of the lack of muscle tissue. The latter could
have serious implications on the prognosis of these
patients.
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Introduction
As spina bifida patients (SB patients) reach adulthood
more often nowadays, clinicians are confronted with
new problems that were not encountered in the past.
SB patients are reported to develop bladder cancer
more often and earlier than their healthy peers.
Several case reports present SB patients with high-
grade, locally advanced bladder carcinoma at rela-
tively young age. We would like to report on the case
of a 31-year-old female SB patient who developed
bladder carcinoma in an auto-augmented bladder.
Case report
A 31-year-old female spina bifida patient presented at
our outpatient clinic in the autumn of 2008. She was
known with a lumbar myelomeningocele (level L3)
with primary closure in early childhood. In 1992, she
had bladder stones removed by transurethral cysto-
lithotripsy. In 1994, she underwent a detrusorectomy
(auto-augmentation; enlargement of bladder capacity
by removal of the muscle layer), rectus-fascia-sling
operation and Mitrofanoff procedure (appendicoves-
icostomy; the creation of an umbilical stoma to facili-
tate easier self-catheterisation). Now, she presented
with complaints of vague aching in the lower abdomen.
She also complained of foul-smelling, cloudy urine.
She did not smoke and used only Metamucil
because of constipation. Physical examination
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revealed no specific signs. Urinalysis showed a
leukocyturia [500/High Power Field (HPF)] and
erythrocyturia (30 erythrocytes/HPF). Urine culture
showed a mixed flora Streptococcus, Bacteroides and
Peptostreptococcus species. Ultrasound of the blad-
der showed a calcification of the bladder wall.
Computed tomography–intravenous pyelography
(CT–IVP) demonstrated a markedly thickened pos-
terior bladder wall. Urethrocystoscopy was extremely
painful. A red, irritated bladder mucosa with oedema
and debris was seen, with a few small bladder stones.
Since this investigation was considered not reliable, a
second urethrocystoscopy under general anaesthesia
was done a few weeks later. An ulcerating tumour
was seen, of which a biopsy was taken. Histological
examination revealed a poorly differentiated transi-
tional cell carcinoma with muscle-invasive growth.
A subsequent MAG3 renography revealed an impaired
drainage of the right kidney and a diminished renal
split function on the right side (L:R = 64%:34%). On
a plain CT abdomen, hydronephrosis and an obstruct-
ing mass at the distal ureter on the right side were seen
(Fig. 1). Besides, para-iliac lymphadenopathy and
induration of perivesical fat were detected. No further
clues for metastasis were seen on chest X-ray and CT
thorax. A nephrostomy tube was inserted to relieve the
right kidney in early December. In mid-December, she
underwent a radical cystectomy and pelvic lymph
node dissection with subsequent Bricker deviation.
At histological examination, a muscle and blood
vessel invasive, poorly differentiated transitional cell
carcinoma with sarcomatoid differentiation was seen.
The tumour measured 10 centimetres with a maximal
infiltration depth of 1.8 centimetres and was removed
radically. One of the para-iliac lymph nodes con-
tained a metastasis of the bladder tumour. Eventually,
the TNM tumour stadium was T3N1M0 (TNM
Classification 2002), grade III (WHO 1973), with
sarcomatoid differentiation. Three months later, at
CT abdomen, large bilateral lymph node masses were
detected, very suggestive for metastasis (Fig. 2).
Also, infiltration to the sigmoid colon was seen, as
infiltration to the iliac veins. She was referred to
medical oncology but found to be unfit for systemic
chemotherapy because of a body weight of 36
kilograms and a poor nutritional status. She was a
candidate for undergoing stenting of the iliac veins,
since pain and oedema developed in the lower
extremities due to venous drainage obstruction in
the small pelvis. However, this was eventually not
done because she developed urosepsis at the day of
operation. Constipation developed because of a mass
effect of the metastases on the sigmoid colon.
The consulting surgeon decided to treat this conser-
vatively. She was referred to a hospice with no
further therapy than adequate analgesia and comfort-
ing and died in June 2009 at the age of 32 years,
about 8 months after diagnosis.
Discussion
We present the case of a 31-year-old female SB
patient with T3N1M0 poorly differentiated transi-
tional cell bladder carcinoma with sarcomatoid
Fig. 1 Computed tomography of the lower abdomen after
biopsy had revealed bladder carcinoma. Note the marked
irregular aspect of the bladder wall, the distal hydroureter at the
right side near the ureterovesical junction
Fig. 2 Computed tomography–intravenous pyelography (CT–
IVP) at the time of metastasis. Two lymph node metastases
(77.4 and 58.2 mm) in the small pelvis are clearly visible
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differentiation. She was relatively young, presented
with lymph node metastasis and muscle-invasive
growth and presented atypically with lower abdom-
inal pain and urinary tract infection. After performing
a literature search, we could only retrieve one other
case report of the same histological type of bladder
cancer with spina bifida (a 32 year-old SB patient
with a grade III T3 tumour with sarcomatoid
differentiation, who was successfully treated by
radical cystectomy and who is free of disease at
9 months of follow-up) [1].
Proposed risk factors of developing bladder
malignancy in SB patients are chronic urinary tract
infection, stone disease and catheterisation and
surgery incorporating enteric segments into the lower
urinary tract like enterocystoplasty [2]. The latter
procedure is often performed in patients with a low
functional bladder capacity. Although functional
outcomes are reported to be good, enterocystoplasty
can give rise to complications like metabolic anom-
alies, urolithiasis and even bladder carcinoma, since
urine is carcinogenic for the enteric mucosa. The
latter issue has also been recognised before in other
urine-storing reservoirs (pouches, neobladders). De-
trusorectomy has been developed in the late 1980s to
offer a less invasive alternative for enterocystoplasty
[3]. One of the possible advantages could be the
lower risk of developing bladder carcinoma. Detru-
sorectomy is not a known risk factor and has only
been reported once before (in a 20-year-old patient
who had pT2N2Mx disease and eventually died
15 months after onset of symptoms) [2]. It is
important to realise that bladder carcinoma not only
develops in patients who underwent augmentation
using enteric segments.
In an auto-augmented bladder, staging of the
primary bladder tumour might pose a challenge
because of the absence of muscle in the bladder
wall. The term ‘muscle-invasive’ does not apply
anymore, and tumours arising in the auto-augmented
part of the bladder cannot be staged as T2. Instead,
every tumour beyond stage T1 is automatically
graded T3 or T4. The difficulty of staging has been
recognised before in elderly patients with bladder
carcinoma in bladder diverticula. In this subset of
patients, rapid invasion of perivesical tissues has
been observed [4]. It seems that the same concepts
could be applied in patients who underwent a
detrusorectomy, since a detrusorectomy is essentially
nothing more than creating a large pseudo-divertic-
ulum on the bladder roof. Taking this into account,
bladder carcinoma arising in the augmented part of
the bladder carries a poor prognosis. In the patient
described in this case report, in biopsy seen after
transurethral resection, muscle was present (the
biopsy was taken next to the ureteral ostia), but the
tumour was very large at presentation and had
already grown into the pseudo-diverticulum.
Although SB patients are theoretically more prone
to develop bladder malignancy, the number of case
reports on this subject is still relatively limited. After
reviewing our own database of 260 adult SB patients
who have been in follow-up in our own centre in the
past decade, only one patient (0.4%) with bladder
cancer was found (which is the one presented here).
Therefore, the exact incidence of bladder cancer in
SB patients remains uncertain.
One earlier series of Page`s et al. [5] presents four
SB patients with bladder cancer with a mean age of
32.75 years. All these patients had undergone enter-
ocystoplasty, and 3 of them performed clean inter-
mittent catheterisation. All had a history of recurrent
urinary tract infections. Presentation varied; only one
patient presented with ‘classical’ painless haematuria,
two with abdominal pain and one with ureteral
obstruction. Three out of four patients presented with
locally advanced disease (T3) or lymph node metas-
tasis at the time of presentation. Austin et al. [6]
presented a series of 8 patients with a mean age of
41 years. Again, a history of chronic infection was
present in all 8 patients; only 1 out of 8 patients had a
history of smoking. Only one patient had undergone
bladder augmentation in the past. Patients presented
with either gross haematuria (n = 5) or renal failure
due to ureteral obstruction (n = 2). Seven of these
patients had a locally advanced tumour or lymph
node involvement at the time of presentation. Median
survival was 6 months in these patients. Subse-
quently, they added an additional 11 patients at their
series which were previously published in the liter-
ature (the series of Austin provides a review of all
case reports until 2007). Median survival (if avail-
able) was 6 months, with locally advanced (T3) or
lymph nodal involvement at the time of presentation
in 15 out of 16 patients with staging data available.
The concepts of increased risk of developing bladder
carcinoma are also (or at least in part) applicable to
patients suffering from other neurological conditions
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causing neurogenic bladder, since they are exposed to
the same risk factors. A 2007 series from Parra et al.
[7] presented 8 patients with spina cord injuries
(n = 4), spina bifida (n = 1) familial spastic tetra-
plegia (n = 1) and idiopathic peripheral syndrome
(n = 1) with bladder cancer. Seven out of eight
tumours were high grade, and the same amount
was muscle-invasive (T2?). After a follow-up of
14–71 months, 3 patients died eventually. Thus, this
series reflects that malignant degeneration of the
bladder does not only occur in spina bifida patients
but may occur in all patients with neurogenic bladder
disorder.
Conclusion
Bladder cancer in adult spina bifida patients may
arise at an early age and may present atypically,
as was demonstrated by our case. It is important that
clinicians are aware of the possibility and the
biological behaviour of bladder cancer in this specific
subset of patients. This is the first case of bladder
carcinoma arising in an auto-augmented bladder in a
spina bifida patient. Bladder carcinoma in an auto-
augmented bladder spreads more easily to perivesical
tissues because of the absent muscle layer.
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